Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Semagacestat in Alzheimer's Disease Patients Completing Phase 3 Double-Blind Studies
2009-014424-29Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of semagacestat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Primary endpoints: Completion of 24-month treatment period and Safety assessments (adverse events, vital signs, laboratory evaluations, ECGs). Started Nov 2009; status: completed.
02
Drugs
semagacestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-014424-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014424-29.